Taysha Gene Therapies, Inc.
TSHA · NASDAQ
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Taysha Gene Therapies, Inc. (TSHA) is a biotechnology company focused on the development of advanced gene therapies for the treatment of rare genetic diseases. The company aims to utilize adeno-associated viruses (AAV) to deliver healthy genes into patient cells, with the goal of correcting genetic defects and providing long-term therapeutic effects. Taysha Gene Therapies targets diseases that cause significant impairment to patients and lack effective treatments. Their research and development in the field of gene therapy offer hope to many individuals and have the potential to change the course of these severe diseases. Investors who track innovations in gene therapy and have an interest in treating rare genetic disorders may see potential in Taysha Gene Therapies, Inc. (TSHA) shares for significant improvement in patients' lives and the growth of this company.
Sector
Healthcare
Industry
Biotechnology
CEO
Sean Nolan
Employees
99
Headquarters
Dallas
Upcoming events
Earnings
Upcoming earnings report